Board of Directors
Stephen Van Deventer
Chairman
Stephen Van Deventer
Chairman
Stephen is the Chairman and CEO of BioGene Therapeutics Inc. and PreveCeutical Medical Inc., with over 30 years of experience in capital markets with a focus on life sciences. Stephen has started and raised millions in the capital markets space and launched companies into the public markets in Canada, the United States and Europe.
Deepak Sampath ,PhD
Deepak Sampath ,PhD
Deepak will serve as an Independent Director for BioGene. He is the Senior VP, Head of Research at Ultragenyx, with previous experience at Pfizer and Genetech, along with several patents in the treatment of cancers. He has extensive experience in small molecules, protein biologics, nucleic acids, and gene therapies. His leadership has driven numerous programs from early research and drug discovery into clinical trials and through regulatory approval for commercialization.
Steve Glover
Steve Glover
Steve joins BioGene as a Board Member, bringing multifaceted experience in Fortune 100 and start-up environments with previous experience at GSK, Roche and Amgen. He sits as Chairman and CEO of Nasdaq-listed ZyVersa Therapeutics PDS Biotechnology and was former Chairman of Ambrx, which was acquired for $2B by Johnson & Johnson. Stephen's operational expertise spans commercialization, integrated product development, and governance, having overseen the development and launch of over 25 products in multiple therapeutic areas.
Patroski J. Lawson, MSP
Patroski J. Lawson, MSP
Patroski is the founder and CEO of KPM Group DC, a strategic public affairs firm. With over 20 years of experience in government affairs, he has worked across local, state, federal, and global levels, including roles at Solvay Pharmaceuticals, Abbott, and Lundbeck. Patroski holds a B.S. in Political Science with a concentration in Urban Geography and an M.S.P. in Urban and Regional Planning, both from The Florida State University.